UNSPSC 51372604: Dimenoxadol

This classification denotes an analgesic agent with the molecular formula C20H25NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4D65PBX0VK, chemically known as 2-dimethylaminoethyl 1-ethoxy-1,1-diphenylacetate but generally known as dimenoxadol, which bears US NIH Compound Identifier 17036. European Medicines Agency schedules Dimenoxadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07160MIG.

UNSPSC 51372604 Dimenoxadol is a Commodity code that in practice captures state and local procurement of naloxone, drug deactivation systems, generic pharmaceuticals, and over-the-counter products for community health and pharmacy benefit programs. State and local governments buying under this code are primarily county health departments, state health and human services agencies, and multistate cooperative purchasing alliances acquiring pharmaceutical inventory and related harm-reduction supplies for public health distribution, emergency response, and employee or Medicaid populations. The scope of work ranges from naloxone and safe drug deactivation systems for community health initiatives to large-scale generic pharmaceutical supply agreements that serve multiple state and local facilities through authorized wholesalers.

Recent activity centers on Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building, with response due July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, reflecting state interest in bypassing traditional pharmacy benefit managers and wholesalers for direct contracting. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to supply participating state and local facilities across multiple states including Oregon, with proposals due March 26, 2026 and contract awards effective July 1, 2026. The MMCAP procurement requires vendors to work through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson) and mandates compliance with current Good Manufacturing Practices, the Drug Supply Chain Security Act, and FDA requirements.